ArticleCancer2014
Expected population impacts of discontinued prostate-specific antigen screening.
Article in Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02799303 (A Randomized Clinical Trial Comparing the Efficacy of MRI Versus PSA for Prostate Cancer Screening), which is not on this map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Clinical Trial Comparing the Efficacy of MRI Versus PSA for Prostate Cancer Screening: The MVP Study (MRI vs PSA)
Who cites it
51 citing papers in PubMed, 97 citations in OpenAlex.
- Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.PloS one · 2017Trial
- A sensitive and specific non-invasive urine biomarker panel for prostate cancer detection.EBioMedicine · 2025Article
- The Influence of Disparities on Prostate Cancer at Diagnosis in the Charlotte Metropolitan Area.Annals of surgical oncology · 2024Article
- Racial disparities in prostate cancer mortality: a model-based decomposition of contributing factors.Journal of the National Cancer Institute. Monographs · 2023Article
- Training Community African American and Hispanic/Latino/a Advocates on Prostate Cancer (PCa): a Multicultural and Bicoastal Approach.Journal of cancer education : the official journal of the American Association for Cancer Education · 2023Article
- Associations of Content and Context of Communication with Prostate-Specific Antigen Testing.International journal of environmental research and public health · 2023Article
- Increasing aggressive prostate cancer.The Canadian journal of urology · 2022Article
- Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations.BMC urology · 2022Article
- Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.NEJM evidence · 2022Article
- Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2021Article
- Impact on prostate cancer clinical presentation after non-screening policies at a tertiary-care medical center- a retrospective study.BMC urology · 2021Article
- Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer.JNCI cancer spectrum · 2021Article
- Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.Journal of the National Cancer Institute · 2021Article
- Inverse Stage Migration in Radical Prostatectomy-A Sustaining Phenomenon.Frontiers in surgery · 2021Article
- Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels.The Prostate · 2020Article
- Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels.Journal of the National Cancer Institute · 2020Article
- Towards personalized prostate cancer screening.Advances in laboratory medicine · 2020Review
- A Trend Toward Aggressive Prostate Cancer.Reviews in urology · 2020Article
- [Trivialization of prostate cancer? : Stage shift and possible causes].Der Urologe. Ausg. A · 2019Article
- Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.The Journal of urology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundProstate-specific antigen (PSA) screening for prostate cancer has high risks of overdiagnosis, particularly among older men, and reports from screening trials indicate that it saves few lives after 11 to 13 years of follow-up. New clinical guidelines recommend against PSA screening for all men or for men aged >70 years, but, to the authors' knowledge, the expected population effects of these guidelines have not been studied to date.
methodsTwo models of prostate cancer natural history and diagnosis were previously developed using reconstructed PSA screening patterns and prostate cancer incidence in the United States. Assuming a survival benefit of PSA screening consistent with the screening trials, the authors used the models to predict incidence and mortality rates for the period from 2013 through 2025 under continued PSA screening and under discontinued PSA screening for all men or for men aged >70 years.
resultsThe models predicted that continuation of recent screening rates will overdiagnose 710,000 to 1,120,000 men (range between models) but will avoid 36,000 to 57,000 cancer deaths over the period 2013 through 2025. Discontinued screening for all men eliminated 100% of overdiagnoses but failed to prevent 100% of avoidable cancer deaths. Continued screening for men aged <70 years eliminated 64% to 66% of overdiagnoses but failed to prevent 36% to 39% of avoidable cancer deaths.
conclusionsDiscontinuing PSA screening for all men may generate many avoidable cancer deaths. Continuing PSA screening for men aged <70 years could prevent greater than one-half of these avoidable cancer deaths while dramatically reducing overdiagnoses compared with continued PSA screening for all ages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.